hPD-L1/hCTLA-4
Nomenclature
C57BL/6JSmo-Ctla4tm1(hCTLA4)Cd274tm1(hPD-L1)Smoc
Cat. NO.
NM-HU-00102
Strain State
Embryo Cryopreservation
Model Description
Validation Data
Fig1 Splenocytes from homozygous hPDL1/hCTLA4 mice were analyzed by flow cytometry after activation. mPDL1+ and mCTLA4+ were detectable in wild type (WT) C57BL/6, while hPDL1+ and hCTLA4+ cells were detectable in the homozygous hCTLA4/h4-1BB mice.
Fig2 hCTLA-4/PD-L1 mice+ MC38 cells efficacy studies. We have developed a CTLA-4/PD-L1 dKI humanized model and tested the combined treatment of Yervoy and Tecentriq, and then observed improved efficacy in the combination treatment.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
